All times are listed in EST (GMT -5).
Current State of SBRT Trials (Panel)
le 2 février 2021 from 14h30 HAE to 16h00 HAE
In this section, participants will have the opportunity to hear from Dr.Zsolt Gabos, Dr. David Palma and Dr. Nick van As about the current state of SBRT trials and data as well as possible future orientations of SBRT treatments. Participants will also have the opportunity to discuss with our panelists afterwards.
Conférenciers / Panélistes
-
Current State of SBRT Trials (Panel)
le 2 février 2021 de 14h30 HAE À 16h00 HAE -
Discussion (panel)
le 1 février 2021 de 12h45 HAE À 13h30 HAE -
Current State of SBRT Trials (Panel)
le 2 février 2021 de 14h30 HAE À 16h00 HAE -
Current State of SBRT Trials (Panel)
le 2 février 2021 de 14h30 HAE À 16h00 HAE -
Current State of SBRT Trials (Panel)
le 2 février 2021 de 14h30 HAE À 16h00 HAE
Zsolt Gabos, MD, FRCPC
Radiation Oncologist
Zsolt Gabos, MD, FRCPC
Zsolt Gabos, MD, FRCPC
Radiation Oncologist
Zsolt Gabos is an associate professor at the University of Alberta and a radiation oncologist at the Cross Cancer Institute. His current practice focuses on the treatment of thoracic and breast malignancies. He is the clinical lead for the stereotactic body radiotherapy (SBRT) program at the Cross Cancer Institute. His research interests include advanced radiotherapy treatment delivery techniques, image guided radiotherapy, SBRT and clinical trials. He graduated from Radiation Oncology Residency at the University of Alberta and completed a fellowship in stereotactic radiosurgery and SBRT at the Tom Baker Cancer Centre, University of Calgary.
Laura Masucci, MD, FRCPC
Radiation Oncologist
Laura Masucci, MD, FRCPC
Laura Masucci, MD, FRCPC
Radiation Oncologist
Dr. Laura Masucci is a radiation oncologist at the Centre Hospitalier de l’Université de Montréal (CHUM). After finishing her radiation oncology residency at the CHUM in 2010, she completed a fellowship at Princess Margaret Hospital specializing in the treatment of primary and secondary brain tumors and radiosurgery of vertebral metastases. She is presently heading the spine SBRT program at the CHUM and is site leader in both CNS oncology and spine SBRT at the department of radiation oncology. She previously served as program director for the radiation oncology residency program at the Université de Montréal. She is now president of the Association of Radiation Oncology of Québec (AROQ).
David Palma, MD, PhD
Radiation Oncologist
David Palma, MD, PhD
David Palma, MD, PhD
Radiation Oncologist
Dr. David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Canada. He holds an MD from the University of Western Ontario, a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group, and the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.
Nicholas van As, MBBCH MRCP FRCR MD(res)
Consultant Clinical Oncologist & Medical Director
Nicholas van As, MBBCH MRCP FRCR MD(res)
Nicholas van As, MBBCH MRCP FRCR MD(res)
Consultant Clinical Oncologist & Medical Director
Dr Nicholas van As was appointed Medical Director of The Royal Marsden NHS Foundation Trust in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden since 2008 and is the hospital’s Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Dr van As is also Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI, and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer.